A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition


AIM: To study the impact of intensified therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor vilagliptin or sulfonylurea (SU) on the control of glycemia, weight, and quantitative body composition in patients with type 2 diabetes mellitus (DM-2) who have failed to achieve compensation during metformin monotherapy/MATERIAL AND METHODS: Forty patients (mean age 55.0 (range 53.0-60.7) years; disease duration 2.0 (range 1.1-5.0) years) with poor glycemic control (7%

Full Text

Restricted Access

About the authors

M V Shestakova

Email: nephro@endocrincentr.ru

O Iu Sukhareva

T O Chernova

I A Shmushkovich

A A Aleksandrov

A V Il'in

I I Dedov


  1. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
  2. Дедов И.И., Шестакова М.В., Сухарева О.Ю. Инновации в лечении сахарного диабета 2-го типа: применение инкретинов. Тер арх 2010; 10: 5-10.
  3. International Diabetes Federation. Treatment Algorithm for People with Type 2 Diabetes. Доступно на http://www.idf.org/treatment-algorithm-people-type-2-diabetes.
  4. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии СД-2-го типа. Сахарный диабет 2011; 4: 6-17.
  5. Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
  6. Hubert H.B., Feinleib M., McNamara P.T., Castell W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants of the Framingham Heart Study. Circulation 1983; 67: 968-977.
  7. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Патогенетические аспекты ожирения. Ожирение и метаболизм 2004; 1: 3-9.
  8. Koenig W., Khuseyinova N., Baumert J. et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middleaged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006; 48: 1369-1377.
  9. Mazess R.B., Barden H.S. Measurement of bone by dual-photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DEXA). Ann Chir Gynaecol 1988; 77 (5-6): 197-203.
  10. Holst J. The physiology and pharmacology of incretins in type 2 diabetes. Diabetes Obes Metab 2008; 10 (Suppl 3): 14-21.
  11. Balas B., Baig M.R. The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients. J Clin Endocrinol Metabol 2007; 92 (4): 1249 -1255.
  12. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin System. Endocrine Rev 2012; 33 (2): 187-215.
  13. Бутрова С.А., Дзгоева Ф.Х. Висцеральное ожирение - ключевое звено метаболического синдрома. Ожирение и метаболизм 2004; 1: 10-13.
  14. Despres J.P. Inflammation and cardiovascular disease: is abdominal obesity the missing link? Int J Obes 2003; 27 (Suppl): 22-24.



Abstract - 54



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies